Calculating Your Business Case For Pharmaceutical Continuous Manufacturing
By Richard Steiner, senior manager, business strategy, Pharmatech Associates
![GettyImages-1177540747 GettyImages-1177540747](https://vertassets.blob.core.windows.net/image/979dc2f0/979dc2f0-29a5-4fcf-a121-b0933bfd5c64/375_250-gettyimages_1177540747.jpg)
Development and commercialization of a drug product in a highly regulated market involves a significant amount of risk. Advanced manufacturing processes such as pharmaceutical continuous manufacturing (PCM) introduces additional risk to the drug life cycle and is often a barrier to implementing any new technology.
Review key considerations as a Pharmatech Associates expert introduces a useful financial equation to calculate amortization to develop the business case for PCM and provides a few real-world cases. Discover how PCM can support specific business needs and how to implement it.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.